Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients

Obtaining a biopsy of solid tumors requires invasive procedures that strongly limit patient compliance. In contrast, a blood extraction is safe, can be performed at many time points during the course disease and encourages appropriate therapy modifications, potentially improving the patient’s clinical outcome and quality of life. Fusion of the tyrosine kinase genes anaplastic lymphoma kinase (ALK), C-ROS oncogen 1 (ROS 1), rearranged during transfection (RET) and neurotrophic tyrosine kinase 1 (NTRK1) occur in 1-5% of lung adenocarcinomas and constitute therapeutic targets for tyrosine kinase inhibitors. In addition, a MET splicing variant of exon 14, has been reported in 2-4% of lung adenocarcinoma and recent studies suggests that targeted therapies inhibiting MET signaling would be beneficial for patients with this alteration. Here, researchers from Pangaea Oncology, summarize the new techniques recently developed to detect ALK, RET, ROS and NTRK1 fusions and MET exon 14 splicing variant in liquid biopsy using plasma, serum, circulating tumor cells (CTCs), platelets and exosomes as starting material.


Workflow of the fusion gene analyses in plasma and platelets-derived RNA using automatic extraction followed by RT-PCR. RT-PCR, reverse transcription-polymerase chain reaction.

Aguado C, Giménez-Capitán A, Karachaliou N, Pérez-Rosado A, Viteri S, Morales-Espinosa D, Rosell R. (2016) Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients. Transl Lung Cancer Res 5(5):525-531. [article]

Leave a Reply

Your email address will not be published. Required fields are marked *